摘要
奥利万星(oritavancin,ORBACTIVTM)是一种新型半合成糖肽类抗菌药物,FDA于2014年8月批准该药用于由敏感革兰阳性菌(包括MRSA)导致的急性细菌性皮肤和皮肤结构感染(ABSSSIs)成人患者的治疗。本文对奥利万星适应证、作用机制、药动学、抗菌活性、临床研究、药品不良反应等进行介绍,以期为临床应用提供参考。
Oritavancin （ ORBACTIV^TM ） is a new semi-synthetic glycopeptide antibacterial agent approved by FDA in August 2014 for the treatment of adult patients with acute bacterial skin and skin structure infections （ABSSSIs） caused by gram-positive bacteria （including methicillin-resistant Staphylococcus aureus, MRSA）. In the review, the indications, action mechanism, pharmacokinetics, antibacterial activity, clinical studies and adverse reactions of oritavanein were introduced in order to provide reference for its clinical application.
出处
《中国药师》
CAS
2015年第7期1208-1210,共3页
China Pharmacist
关键词
奥利万星
糖肽类抗菌药物
急性细菌性皮肤和皮肤结构感染
Oritavancin
Glycopeptide antibacterial agent
Acute bacterial skin and skin structure infections
